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Neutralizationis caused by four genetically and serologically related viruses termed DENV-1,
-2, -3, and -4. The DENV envelope (E) protein ectodomain can be divided into three structural domains
designated ED1, ED2, and ED3. The ED3 contains the DENV type-speciﬁc and DENV complex-reactive
(epitopes shared by DENV 1–4) antigenic sites. In this study the epitopes recognized by four DENV
complex-reactive monoclonal antibodies (MAbs) with neutralizing activity were mapped on the DENV-3
ED3 using a combination of physical and biological techniques. Amino acid residues L306, K308, G381,
I387, and W389 were critical for all four MAbs, with residues V305, E309, V310, K325, D382, A384, K386,
and R391 being critical for various subsets of the MAbs. A previous study by our group (Gromowski, G.D.,
Barrett, N.D., Barrett, A.D., 2008. Characterization of dengue complex-speciﬁc neutralizing epitopes on the
envelope protein domain III of dengue 2 virus. J. Virol 82, 8828–8837) characterized the same panel of
MAbs with DENV-2. The location of the DENV complex-reactive antigenic site on the DENV-2 and DENV-
3 ED3s is similar; however, the critical residues for binding are not identical. Overall, this indicates that
the DENV complex-reactive antigenic site on ED3 may be similar in location, but the surprising result is
that DENV 2 and 3 exhibit unique sets of residues deﬁning the energetics of interaction to the same
panel of MAbs. These results imply that the amino acid sequences of DENV deﬁne a unique interaction
network among these residues in spite of the fact that all ﬂavivirus ED3s to date assume the same
structural fold.
© 2008 Published by Elsevier Inc.IntroductionThe disease dengue (DEN) is caused by four serologically and
genetically related viruses, termed DENV types 1–4, which belong to
the genus Flavivirus, family Flaviviridae. Dengue is the most important
mosquito-borne viral disease in terms of the number of cases each
year and its geographic distribution (Gubler, 2004). Over 3 billion
people, in more than 100 countries, are at risk from DENV infection,
with at least 50 million infections each year. Clinical symptoms range
from a self-limited, acute, febrile disease called DEN fever (DF) to the
more severe DEN hemorrhagic fever (DHF), and DEN shock syndrome
(DSS) (Halstead, 2007). The DENVs are single-stranded, positive-sense
RNA viruses with a genome of approximately 11 kb. The genome
contains a single open reading frame encoding three structuralUniversity of Texas Medical
2 2500.
lsevier Inc.proteins: capsid (C), pre-membrane/membrane (prM/M), and a
major envelope glycoprotein (E) and seven nonstructural proteins
(Rice et al., 1985). The DENV E protein has three domains: a central β-
barrel (domain I: ED1), an elongated dimerization region (domain II:
ED2), and a C-terminal immunoglobulin (Ig)-like module (domain III:
ED3) (Rey et al., 1995). The DENV ED3 contains type-speciﬁc and
complex-reactive (i.e., epitopes shared by DENV 1–4 only) epitopes
that are the dominant neutralization determinants (Roehrig, 2003). In
this study, we analyzed epitopes on the DENV-3 ED3 that are re-
cognized by DENV complex-reactive monoclonal antibodies (MAbs).
These were characterized by a combination of physical binding of
MAbs to a recombinant ED3 (rED3), epitope mapping using rED3
mutants, and biological activities of neutralization and hemagglutina-
tion inhibition. Interestingly, the antigenic site recognized by this
panel of DENV complex-reactive MAbs on the DENV-2 ED3 (Gro-
mowski et al., 2008) was in a similar location on the DENV-3 ED3.
However, in this study, we show that the critical residues for binding
varied signiﬁcantly for the DENV-3 ED3. This indicates that the DENV
Table 2
Relative Kd for each MAb/rED3 mutant combination
Number of
amino acid
Different of anti DENV MAbs
MDVP-55A GTX29202 MA1-27093 20-783-74014
DENV-3 wt 1.00 1.00 1.00 1.00
L301G 5.74 2.43 2.34 2.48
T303A 1.40 1.89 2.00 3.34
T303K 2.69 6.69 1.86 1.40
T303S 0.70 1.19 N48 2.74
V305G N78 19.49 4.70 9.39
L306G N78 N64 N48 N32
K307G 0.21 0.18 0.17 0.42
K308A N78 54.89 N48 N32
K308G N78 N64 N48 N32
K308Q N78 N64 N48 N32
E309G N78 28.67 N48 6.91
V310G 5.92 N64 N48 N32
K321G 1.64 1.30 1.04 2.25
K325G N78 32.70 5.92 N32
A329G 7.99 N64 1.34 N32
G381E 24.43 14.13 N48 N32
D382E 3.55 1.96 2.97 17.32
D382G 6.36 7.82 2.04 6.73
D382N 3.18 1.62 0.71 0.90
D382P 4.44 2.70 6.60 16.35
K383G 8.86 3.05 6.54 9.06
A384Q 12.86 9.89 N48 N32
K386G 0.45 37.42 N48 N32
K386N N78 3.41 0.60 N32
I387G N78 N64 34.06 N32
W389G N78 N64 N48 N32
R391G N78 8.46 34.18 N32
The effects of mutations in ED3 are classiﬁed as either weak changes (in italics) and
strong changes (in bold).
17Rapid Communicationcomplex-reactive antigenic site on ED3 may be similar in location, but
unique in amino acid composition in deﬁning the energetics of
interaction between DENV ED3s andMAbs for each of the four DENVs.
Results
Characterization of MAbs
The binding of four afﬁnity puriﬁed IgG2a MAbs (MDVP-55A,
GTX29202, MA1-27093, and 20-783 -74014) to DENV-3 and DENV-2
were compared by indirect ELISA, HI, and PRNT50. All four MAbs
demonstrated tighter binding to DENV-2 rED3 than to DENV-3 rED3
with Kds ranging from0.5±0.1 nM to 0.7±0.2 nM for the DENV-2 rED3
and 2.5±0.2 nM to 7±1 nM for the DENV-3 rED3 (Table 1). The PRNT50
concentration was determined for each of the four DENV complex-
reactive MAbs with DENV-2 and DENV-3. The four MAbs had PRNT50
values with DENV-3 that ranged from 150±10 nM to 279±7 nM,
which was signiﬁcantly higher than the physical binding Kd that
ranged from 2.50±0.2 nM to 7±1 nM. Similar results were obtained
for DENV-2. The ratio of PRNT50 values to Kd values (i.e., PRNT50/Kd)
was calculated as it reﬂects the magnitude of the shift of the PRNT
curve relative to the physical binding curve (Table 1). For DENV-3 the
PRNT50 to Kd ratio was large (greater than 20-fold) for all four MAbs
indicating that there was a large shift of the PRNT curve to the right
and away from the physical binding curve. The PRNT50 to Kd ratio for
DENV-3, compared to DENV-2, was higher with MAbs MDVP-55A and
20-783-74014, but similar for MAbs GTX29202 and MA1-27093
(Table 1) indicating that the MAbs neutralized DENV-3 weaker than
DENV-2 evenwhen the physical binding was normalized. In HI assays,
the MAbs had titers for DENV-3 ranging from 25 nM to 67 nM and
these values were much higher than the HI titers previously reported
for this set of MAbs with DENV-2 (Gromowski et al., 2008) (Table 1).
Binding afﬁnity of MAbs with rED3 mutants
A total of 27 single amino acid substitutions were introduced into
the DENV-3 rED3 by site-directed mutagenesis at 19 different surface
accessible residues that were selected based on the published
structure of the DENV-3 E protein (Modis et al., 2005) and previous
studies with DENV-2 (Gromowski et al., 2008). The Kd for each of the
four DENV complex-reactive MAbs was determined by titration in an
indirect ELISAwith each of the 27 rED3mutant proteins and compared
to the wild-type DENV-3 rED3 (Table 2). The importance of residues
for MAb binding was analyzed as previously described by Gromowski
and Barrett (2007) where mutant proteins resulting in a change in Kd
of between 4- and 10-fold were considered “weak” changes in afﬁnity
(italicized in Table 2) and those having a change in afﬁnity that was
greater than 10-fold were considered “strong” changes (bolded in
Table 2). Mutations that resulted in weak and strong changes in
afﬁnity are summarized in Fig. 1.
Epitope analysis
The epitope analysis was carried out in a similar manner to that
described by Gromowski and Barrett (2007). Those mutations thatTable 1
A comparison of the Kd, PRNT50, and HI titer for the DENV complex-reactive MAbs with DE
DENV MAbs Kd (nM) PRNT50 (nM
DEN3V DEN2V DEN3V
MDVP-55A 2.50±0.24 0.52±0.11 176.8±12.8
GTX29202 7.30±1.04 0.44±0.02 148.3±14.3
MA1-27093 6.49±1.04 0.43±0.03 159.9±12.7
20-783-74014 5.78±1.20 0.73±0.15 278.5±6.5
a The Kd values with DENV-2 virus PRNT50 and HI concentrations were previously reporthad a “strong” effect (i.e., greater than 10-fold change in Kd) on MAb
binding afﬁnity were considered as being critical epitope residues.
Overall, the four MAbs were found to involve a total of 13 residues in
ED3 but only L306, K308, G381, I387 and W389 (Fig. 1a, colored red)
were shared by all four MAbs. The other nine residues were muta-
tions that had a “strong” or “weak” effect depending on the par-
ticular MAb. These residues were as follows: V305, E309, V310, K325,
D382, A384Q, K386, and R391 (Fig. 1a, colored pink). Overall, the
four DENV complex-reactive MAbs recognize a set of overlapping
epitopes that form a single antigenic site on the lateral surface of
ED3.
Comparison of DENV complex-reactive antigenic site on DENV-2 and
DENV-3 ED3s
The DENV-3 ED3 is 100 amino acids and consists of residues 293 to
393 of the E protein. The DENV-2 ED3 is also 100 amino acids; but the
entire E protein is two amino acids longer and so the numbering of
DENV-2 ED3 is from 295 to 395 of the E protein. The DENV complex-
reactive antigenic site was localized to amino acids on analogous
surfaces of ED3 for DENV-3 and DENV-2 (Figs. 1c and d, respectively).
Amino acid residues L306, K308, G381, I387, and W389 were critical
for all fourMAbs on the DENV-3 ED3 and are equivalent to V308, K310,
E383, L389 and W391 on the DENV-2 ED3. Residue K310 for DENV-2
(K308 for DENV-3) was the only common critical amino acid forNV-2 and -3
) Ratio PRNT50/Kd HI titer (nM)
DEN2Va DEN3V DEN2V DEN3V DEN2Va
3.0±0.2 70.7 5.8 25.0 0.63
5.9±0.3 20.3 13.4 25.0 0.94
7.5±0.5 24.6 17.4 50.0 1.25
11.8±1.3 48.2 16.2 66.7 1.25
ed (Gromowski et al., 2008).
Fig.1. Comparison of DENV complex-reactive MAb epitopes on DENV-2 and DENV-3 ED3s. The Kd of the 4 DENV complex-reactive MAbs was determined by titration in an indirect
ELISA with the DENV-3 rED3 protein. The substitutions that resulted in a change in binding afﬁnity between 4- and 10-fold were deﬁned as having weak effects on the binding
afﬁnity (colored pink). Substitutions that resulted in a greater than 10-fold change in binding afﬁnity were considered a strong effect (colored red). (a) Critical residues for all 4
MAb with the DENV-3 ED3 were L306, K308, G381, I387, W389, and R391. (b) For DENV-2, the only shared critical residue for the four MAbs was residue K310 (K308 is equivalent
for DENV-3) as reported by Gromowski et al. (2008) All of the critical residues within the DENV complex-reactive antigenic site for DENV-3 are in panel (c) and DENV-2 is in panel
(d) for comparison.
18 Rapid Communicationbinding of the DENV complex-reactive MAbs on the DENV-2 and -3
ED3s (Fig. 1b and Gromowski et al., 2008).
Discussion
Successful development of a tetravalent vaccine for DEN depends
on better knowledge on the interactions between DENV complex-
speciﬁc MAbs and the complex-reactive epitopes. With this in mind,
we wanted to determine the physical location and characteristics of
the complex-reactive epitopes on the structures of these ED3s. We
also want to understand the determining factors that deﬁne the
energetics of MAbs interacting with the ED3s. We have previously
reported the characterization of a panel of DENV complex-speciﬁc
MAbs with DENV-2 ED3 (Gromowski et al., 2008) and in this study we
did a similar characterization of the physical binding and biological
properties of this panel of MAbs with DENV-3 ED3. The bindingafﬁnity of MAbs to the DENV-2 rED3 was about 5- to 17-fold tighter
compared to the binding afﬁnity for the DENV-3 rED3, depending on
the MAb. In accordance with these results, the PRNT50 concentrations
for DENV-2 were about 20- to 50-fold lower, depending on the MAb,
compared to the PRNT50 concentrations with DENV-3. This is in
agreement with results that were previously reported by Gromowski
et al. (2008) using this panel of DENV complex-reactive MAbs and
further demonstrates that there is an excellent correlation between Kd
and PRNT50 for DENV ED3-speciﬁc MAbs. This relationship was also
seen in the HI assays, where the HI titer with DENV-2was about 30- to
50-fold higher compared to DENV-3, depending on the MAb. Overall,
all four MAbs had greater binding afﬁnity (6- to 17-fold higher) and
neutralizing activity (20- to 71-fold higher) with DENV-2 compared to
DENV-3 for the four MAbs studied. Furthermore, when the physical
binding was normalized, the four MAbs neutralized DENV-3 weaker
compared to DENV-2 (see Table 1). Thus, for both DENV-2 and DENV-3
19Rapid Communicationthe efﬁciency of neutralization of this panel of MAbs does not
quantitatively track the afﬁnity of MAb binding to ED3, implying that
neutralization is a composite of more complex reactions than simply
binding to ED3.
In this study, we identiﬁed ﬁve residues (L306, K308, G381, I387,
and W389) that were critical for binding all four DENV complex-
reactive MAbs to the DENV-3 ED3. In comparison, Gromowski et al.
(2008) reported that K310 was the only shared critical residue
required for binding to the DENV-2 ED3 using this same panel of
MAbs. Thus, each species of DENV has unique residues that are critical
to the recognition of even the same MAbs. This conclusion is
consistent with the report by Sukupolvi-Petty et al. (2007) that
residue K310 was a shared critical residue on the DENV-2 ED3 for two
DENV subcomplex-reactive MAbs. Moreover, Lisova et al. (2007)
characterized a DENV complex-reactive epitope on ED3 of DENV-1,
recognized byMAb 4E11, which was found to consist of residues K307,
L308, E309, K310, E311, V312, L387, L389, and W391.
A comparison of critical residues located within the DENV
complex-reactive antigenic site on the DENV-2 and DENV-3 ED3s
revealed that the location and biochemical properties of four of the
shared critical residues are conserved. These residues are K308, V310,
I387, and W389 for DENV-3, with the equivalent residues for DENV-2
being K310, I312, L389, and W391, respectively (see Figs. 1c and d).
Since the structural fold of ED3 of DENV-2 and DENV-3 are essentially
identical (RMSD of the Cα atoms is 0.84 ) (Modis et al. 2005) this
result indicates that the physical locations of the complex-species
epitope are very similar, if not identical. This may be one explanation
for why the panel of MAbs characterized in this study is capable of
recognizing both DENV-2 and DENV-3. If the interfacial interactions
between ED3 andMAb deﬁne the energetics of MAb binding, then one
can expect a difference in the side-chain in the corresponding residue
would lead to the differences in Kd values between DENV-2 and
DENV-3 that we have observed (Table 1, columns 2 and 3). However,
an unexpected result is the additional number of residues whose
mutation can lead to signiﬁcant changes in binding afﬁnity. These
additional critical residues included V305, L306, E309, G381, A384,
and K386, and were not critical residues in the DENV complex-reac-
tive antigenic site on the DENV-2 ED3. In particular, the biochemical
properties of residues K307, E383, and Q386 for DENV-2 (V305, G381,
and A384, respectively for DENV-3) are signiﬁcantly different and this
may explain differences in the reactivity of DENV complex-reactive
MAbswith the DENV-2 and -3 ED3s. These results imply that although
the ED3s assume an essentially identical fold, the differences in the
amino acid sequences deﬁne a different network of interactions
among various residues. The consequence of this difference in
sequence leads to the unique set of residues that deﬁnes the ener-
getics for MAb binding.
Overall, this study demonstrates that the location of the DENV
complex-reactive antigenic site on ED3 for DENV-2 and -3 is
conserved, as are several critical residues for MAb binding. However,
the data indicate that unique critical epitope residues on ED3 may
be important for each of the four DENVs. The results of this study,
therefore, provide insight into how DENV complex-reactive MAbs
are capable of recognizing multiple DENV ED3s. In addition, we give
evidence that structural and biochemical differences within the
DENV complex-reactive antigenic site on the DENV-2 and -3 ED3s




Monkey kidney Vero cells were maintained in Dulbecco's modiﬁed
essential media (DMEM) supplemented with 8% fetal bovine serum
(FBS) and were incubated at 37 °C in a 5% CO2 incubator. Mosquito C6/36 cells were maintained at 28 °C in DMEM containing 10% FBS and
supplemented with tryptose phosphate buffer. DENV-3 strain H87
was used in this study. It was passaged in C6/36 cells and was used as
antigen for the hemagglutination inhibition (HI) assays and virus for
plaque reduction neutralization tests (PRNT50) to characterize the
DENV complex-reactive MAbs.
Cloning, expression and puriﬁcation of recombinant DENV-3 ED3
The DENV-3 rED3 was constructed as previously described
(Gromowski and Barrett, 2007). Brieﬂy, the ED3 region of the DENV-
3 strain H87 was reverse transcription-PCR ampliﬁed for cloning and
expression as maltose binding protein (MBP) fusions using the pMal-
c2x system (New England Biolabs, Beverly, MA). RNA was extracted
from virus-infected cell culture supernatant using the Qiagen Viral
RNA Extraction Kit (Qiagen). Reverse transcription-PCR was under-
taken using the Titan Kit (Roche). The primers used (Forward: 5′-
CGAGGGAAGGATTTCAAAGGGGATGAGCTATGCAATG-3′ and Reverse:
5′-GCCAAGCTTTCATCCCTTCCTGTACCAGTTGATTTTCA-3′) were
designed for cloning into the pMal-c2x vector and contained XmnI
and HindIII ED3 restriction sites, respectively. The recombinant ED3
(rED3) proteins were expressed in Escherichia coli as fusion protein
with MBP as the fusion partner. Expression and puriﬁcation were
undertaken by following the manufacturer's instructions and as
previously described (Beasley and Barrett, 2002).
Dengue-complex speciﬁc monoclonal antibodies (MAbs)
Four commercially available MAbs were used in this study: MDVP-
55A (Immunology Consultants Laboratory, Inc.), GTX29202 (GeneTex),
MA1-27093 (Afﬁnity BioReagents), and 20-783-74014 (GenWay).
These MAbs were afﬁnity puriﬁed IgG2a mouse MAbs and have
been previously reported by Gromowski et al. (2008).
Mutagenesis of recombinant DENV-3 ED3
Site-directed mutagenesis of the DENV-3 H87 ED3 gene fragment
in the pMal-c2x vector was undertaken using the Quickchange kit
(Stratagene, La Jolla, CA) according to the manufacturer's instructions.
Indirect ELISA
An indirect ELISAwas used to investigate the binding of the DENVs
MAbs to DENV-3 strain H87 rED3 as described by Gromowski and
Barrett (2007) and the data shown as apparent Kd value since they
have been determined by an ELISA technique.
Afﬁnity measurements by indirect ELISA
A total of 27 single amino acid substitutions were selected and
evaluated using an indirect ELISA as previously described (Gromowski
and Barrett, 2007).
HI assay
The HI assays were performed as previously described (Clarke and
Casals, 1958). HI assays were carried out at pH 6.0 with goose
erythrocytes using four hemagglutinating units of DENV-3 strain H87.
The titer was deﬁned as the maximum dilution at which hemagglu-
tinationwas completely inhibited andMAb titrations were carried out
in serial two-fold steps starting at 200 nM.
Plaque reduction neutralization test (PRNT50)
The four MAbs were diluted to 1000 nM in PBS. Two-fold serial
dilutions were prepared and mixed with an equal volume of DENV-3
20 Rapid Communication(∼50 pfu/well). Virus and MAb mixtures were incubated for 1 h at
room temperature. Subsequently, the virus-MAb mixture was trans-
ferred to ∼80% conﬂuent Vero cells in 6-well plates. After 1 h of
incubation at room temperature, cell monolayers were overlaid with
MEM containing 2% FBS and 1% Agar, and incubated at 37 °C. Plaques
were observed until visualizing by staining with neutral red. PRNT50
data were converted to percent neutralization relative to controls in
the absence of MAb and PRNT50 concentrations were calculated by
doing a non-linear regression analysis using Sigmaplot (Version 9.01,
Systat Software, Inc., CA) as previously described (Gromowski and
Barrett, 2007).
Statistical analysis
The Kd values are presented as mean±standard error of the mean
(SEM) and were analyzed using SigmaStat (Version 3.1, Systat
Software, Inc., CA).
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